tbuckley/cabot-search huggingface dataset:
Trends and Outcomes of Venous Thromboembolism in Hospitalized Patients with Pancreatic Cancer: Results from National Inpatient Sample Database 1998-2016
Authors: Hussam Alhasson, Peng Cai, Zimu Gong, Anas Saad, Muneer Al-Husseini, Pei Yang, Bassam Alhasson, Pratyusha Tirumanisetty, Tausif Syed, Yu Zhao
Journal: Blood (2019)
P2.03 Normalization of Carcinoembryonic Antigen Levels Are Associated with a Survival Improvement in Advanced Non-Small Cell Lung Cancer Patients
Authors: R. Sánchez Reyes, F. Barrón, L. Cabrera, M.P. Peralta Álvarez, L. Zatarain Barron, A. Pereira-García, E. Varela Santoyo, L. Corrales-Rodriguez, C. Martín, A.F. Cardona, O. Arrieta
Journal: Journal of Thoracic Oncology (2019)
Disseminated Bacillus Calmette-Guérin (BCG) infection with pulmonary and renal involvement: A rare complication of BCG immunotherapy. A case report and narrative review
Authors: Marta Marques, Dolores Vazquez, Susana Sousa, Gonçalo Mesquita, Maria Duarte, Rosa Ferreira
Journal: Pulmonology (2019)

Intravesical Bacillus Calmette-Guérin (BCG) instillation is a mainstay of adjunctive therapy for superficial bladder cancer that increases length of disease progression-free survival. Although usually well tolerated, moderate to severe local and systemic infectious complications can occur with this immunotherapy. Diagnosis is difficult and often based on high clinical suspicion since in many cases Mycobacterium bovis is not isolated. Treatment is not fully standardized but the combination of anti-tuberculosis drugs and corticosteroids is advocated in severe cases. The authors present an unusual case of a severe infectious complication following intravesical BCG instillation with pulmonary and kidney involvement. Prompt anti-tuberculosis treatment associated to corticosteroid resulted in a marked clinical and radiological improvement, supporting the diagnosis of disseminated BCG infection. Based on this, the authors aimed to review the literature on this exceptional complication of this immunotherapy.
CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma
Authors: Jennifer Watkins-Yoon, Wilson Guzman, Amanda Oliphant, Sara Haserlat, Alan Leung, Claire Chottin, Michael Ophir, Jai Vekeria, Allison P Nelson, Zach Frye, Jason Lajoie, Puru Nanjappa, Sujan Lama, Dalton Markrush, William McConaughy, Xianzhe Wang, Neal Schilling, Doyeob Kim, Paul Wu, Lucy Liu, Kenneth Rogers, Francois Villinger, Bing Gong, Stephen Hamilton, Piotr Bobrowicz, Thomas Schuetz, Michael Schmidt, Monia Draghi
Journal: Blood (2019)
Similar Hemostatic Responses to Hypovolemia in Hemorrhage and Lbnp Reveals a Hyperfibrinolytic Subset of Baboons
Authors: Maryanne Herzig, Morten Zaar, Chriselda Fedyk, Bijaya Kumar Parida, Carmen Hinojosa-Laborde, Robert E Shade, Heather F. Pidcoke, Victor A Convertion, Andrew P. Cap
Journal: Blood (2019)
ACTR-63. PHASE I DOSE ESCALATION STUDY OF PROCASPASE ACTIVATING COMPOUND-1 (PAC-1) IN COMBINATION WITH TEMOZOLOMIDE IN PATIENTS WITH RECURRENT ANAPLASTIC ASTROCYTOMA OR GLIOBLASTOMA
Authors: Matthias Holdhoff, Martin Nicholas, Richard Peterson, Oana Danciu, Stefania Maraka, Paul Hergenrother, Theodore Tarasow, Arkadiusz Dudek
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Procaspase activating compound -1 (PAC-1) is a small molecule that catalyzes conversion of procaspase-3 to caspase-3 which induces apoptosis in cancer cells. Glioblastoma (GBM) is among the tumors with high concentrations of procaspase-3 and low levels of caspase-3. PAC-1 crosses the blood brain barrier and has been shown to synergize with temozolomide (TMZ) in canine malignant glioma and meningioma that arise spontaneously. METHODS This is a multicenter phase 1 dose-escalation study to assess the maximum tolerated dose (MTD) of PAC-1 administered days 1–21 in combination with TMZ days 8–12 at a dose of 150 mg/m2 of each 28 day cycle in subjects with recurrent anaplastic astrocytoma (AA) or GBM. A modified Fibonacci 3 + 3 design is used with up to 4 dose levels of PAC-1 (375, 500, 625 and 750 mg/day). Neurologic toxicity, including cognitive function, is closely monitored throughout the trial. INTERIM DATA: A total of 14 subjects have been enrolled to-date. Of these, 7 at dose level 1, PAC-1 375 mg/day (6 GBM, 1 AA; median age 58y, range 25–75) and 7 at dose level 2, PAC-1 500 mg/day (5 GBM, 2 AA; median age 51y, range 35–60). Best responses to-date were 2 subjects with a partial response and 2 with stable disease. Grade 3 (hepatotoxicity) and 4 (cerebral edema) was reported as possibly related to PAC-1 in 1 patient at dose level 1. The median number of cycles received was 4 (range, 1–12+) at dose level 1 and 2 (range, 1–3) at dose level 2. Enrollment to dose level 2 has been completed and data analysis is ongoing. Updated response and toxicity as well as pharmacokinetic data will be presented.
Impact of β-catenin phosphorylation patterns on tumour control/progression in a prospective cervical cancer study (RAIDs)
Authors: S. Scholl, A. Latouche, L. De Koning, M. Popovic, A. de la Rochefordière, E. Berns, P. Gestraud, E. Girard, C. Lecerf, H. von der Leyen, S. Roman Roman, R. Rouzier, M. Kamal, R. Consortium
Journal: Annals of Oncology (2019)
Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
Authors: Pau Abrisqueta, Juan-Manuel Sancho, Raul Cordoba, Daniel O. Persky, Charalambos Andreadis, Scott F. Huntington, Cecilia Carpio, Daniel Morillo Giles, Xin Wei, Ying Fei Li, Marlene Zuraek, Michael R. Burgess, Kristen Hege, Alejandro Martín
Journal: Blood (2019)
Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients with Multiple Myeloma
Authors: Marion Eveillard, Even H Rustad, Mikhail Roshal, Yanming Zhang, Amanda Kathryn Ciardiello, Neha Korde, Malin Hultcrantz, Hani Hassoun, Eric L Smith, Alexander M. Lesokhin, Sham Mailankody, Ola Landgren, Katie Thoren
Journal: Blood (2019)
SURG-28. RADIOFREQUENCY ABLATION AS AN ADJUNCT FOR PAIN AND TUMOR CONTROL IN SPINAL METASTATIC DISEASE
Authors: Tony Urbisci, Bryan Thomas, Nam Tran
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The spine, particularly the thoracolumbar region is a common site for metastatic spread from a variety of primary cancer types. Radiofrequency ablation (RFA) of these lesions has proven efficacious for pain control, but the addition of adjunctive radiation therapy (XRT) remains the standard of care for pain palliation and to prevent tumor progression. OBJECTIVE This study aims to investigate RFA as a standalone intervention to treat and prevent the progression of metastatic vertebral lesions. Study Design: Single center retrospective review of patients receiving RFA for vertebral metastatic lesions between 2013 and 2016. Twenty-nine spinal lesions in nineteen patients were treated with RFA followed by vertebral augmentation. Primary tumors were from prostate, renal cell, breast, lung, laryngeal, multiple myeloma, cervix, thyroid, and colon. The treated levels were then followed with either MRI, PET CT, or CT at varying intervals per the primary oncologist. We compared the duration between the procedure and either first imaging evidence of tumor progression at the treated level or patient death between patients that underwent RFA alone or with the addition of adjunctive XRT. RESULTS Our comparison shows no significant difference (p &lt; 0.357) between the time to progression between the group that received RFA alone and the group that received RFA in conjunction with XRT. CONCLUSION Radiofrequency ablation is a safely and effectively used in the treatment of vertebral metastatic osseous lesions. Although the sample size is small, and the patient population is heterogenous, there is supporting evidence that targeted RFA is as effective in preventing local tumor progression as the procedure combined with XRT.
A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against Beti-Resistant Leukemia Cells
Authors: Lei Guo, Jia Li, Hongxiang Zeng, Anna Guzman, Tingting Li, Minjung Lee, Yubin Zhou, Clifford Stephan, Peter J.A Davies, Margaret Goodell, Deqiang Sun, Mark A. Dawson, Yun Huang
Journal: Blood (2019)
Single Cell Clones Derived from a Patient's AML Xenograft Display Genetic and Functional Heterogeneity
Authors: Christina Maria Zeller, Daniel Richter, Binje Vick, Tobias Herold, Johannes Bagnoli, Maja Rothenberg-Thurley, Klaus H. Metzeler, Karsten Spiekermann, Wolfgang Enard, Irmela Jeremias
Journal: Blood (2019)
Intragraft donor-specific antibodies and lung transplantation
Authors: Jussi M. Tikkanen, Kathryn Tinckam
Journal: European Respiratory Journal (2019)

<b>Intragraft DSA can be found in explanted lungs of patients with chronic lung allograft dysfunction in the absence of circulating DSA. New diagnostic approaches to assess for intragraft DSA may add to our diagnostic arsenal in treating AMR.</b>http://bit.ly/31kS00b
The Presence of Minimal Residual Disease, As Determined By Highly Sensitive Quantitation of NPM1-Mutatation, Provided Powerful Prognostic Information in Acute Myeloid Leukemia
Authors: Atsushi Marumo, Hiroki Yamaguchi, Yuho Najima, Kensuke Usuki, Shinichi Kako, Hitoji Uchiyama, Yuhei Nagao, Katsuhiro Shono, Saiko Kurosawa, Masao Hagihara, Junya Kanda, Yasushi Kubota, Jun Ando, Kenta Date, Marika Kuboyama, Masahiro Sakaguchi, Shunsuke Yui, Satoshi Wakita, Kunihito Arai, Tomoaki Kitano, Kazuhiko Kakihana, Takahiro Fukuda, Noriko Doki, Kazuteru Ohashi, Koiti Inokuchi
Journal: Blood (2019)
Telomere Shortening By Terc Knockout in the Eµ-TCL1 Transgenic Murine Model of CLL: Characterization of Disease Development and Survival
Authors: Billy Michael Chelliah Jebaraj, Annika Scheffold, André Lechel, Sarah-Fee Katz, Eugen Tausch, Johannes Bloehdorn, Daniela Steinbrecher, Vanni Torresi, Christof Schneider, Hartmut Döhner, Daniel Mertens, Lenhard Rudolph, Stephan Stilgenbauer
Journal: Blood (2019)
Autologous Stem Cell Transplantation in Multiple Myeloma Patients Older Than 65 Year-Old, 12-Years Analysis of National Cancer Database
Authors: Veli Bakalov, Amulya Yellala, Raed Benkhadra, Thejus Jayakrishnan, Yazan Samhouri, John Lister, Santhosh Sadashiv, Rodney E Wegner
Journal: Blood (2019)
SCIDOT-25. ENHANCING THE EFFICACY OF DRUG RELEASED FROM LOADED FIBRIN GLUE BY PHOTOCHEMICAL INTERNALIZATION (PCI)
Authors: Henry Hirschberg, Lina Nguven, Julie Johnsen
Journal: Neuro-Oncology (2019)

Abstract Although gross total resection of gliomas is often possible with current available techniques, almost all tumors recur due to the infiltrative nature of these tumors. Infiltrative tumor cells in normal brain are consequently protected by the blood brain barrier (BBB), greatly reducing the efficacy of chemotherapy. Localized per-operative methods of slow-release drug delivery, that bypass the BBB altogether, are therefore of considerable interest. Fibrin glue (FG) is a FDA approved compound often used during surgery. FG loaded with drugs has been studied as a localized controlled release vehicle but the quantity and release kinetics attainable for some drugs using FG are often inadequate. Photochemical internalization (PCI) has been demonstrated to significantly enhance the efficacy of several chemo-theraputic agents such as bleomycin (BLM) and doxorubicin (DOX). In particular PCI of BLM has been shown to be effective in sterilizing the tumor bed after marginal cytoreductive surgery. We have evaluated the ability of PCI to enhance the ability of BLM and DOX, released from loaded FG, to inhibit the growth of multi-cell glioma spheroids in vitro. Spheroid growth was monitored for 14 days. The results of the present study show that drug was released for up to 72 hours. The growth inhibition caused by either BLM or DOX was significantly enhanced by PCI. The photosensitizer AlPcS2a could also be loaded and released from FG allowing local delivery at the tumor site.
Data must be shared—also with researchers outside of Europe
Authors: Giske Ursin, Magnus Stenbeck, Jenny Chang-Claude, Marc Gunter, Rudolf Kaaks, Ellen Kampman, Mats Lambe, Flora van Leeuwen, Patrik Magnusson, Nea Malila, Mef C Nilbert, Pål R Romundstad, Martin Röösli, Anne Lise Ryel, Isabel dos-Santos-Silva, Hans H Storm, Anthony Swerdlow, Paolo Vineis, Gun Peggy S Knudsen
Journal: The Lancet (2019)
Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone
Authors: Samih H. Nasr, Christopher P. Larsen, Christophe Sirac, Jason D. Theis, Camille Domenger, Sophie Chauvet, Vincent Javaugue, Jonathan J. Hogan, Samar M. Said, Surendra Dasari, Julie A. Vrana, Ellen D. McPhail, Lynn D. Cornell, Eve Vilaine, Ziad A. Massy, Jean-Jacques Boffa, David Buob, Stéphanie Toussaint, Thomas Guincestre, Guy Touchard, Vivette D. D’Agati, Nelson Leung, Frank Bridoux
Journal: Kidney International (2019)
Conflicting verdicts on peanut oral immunotherapy from the Institute for Clinical and Economic Review and US Food and Drug Administration Advisory Committee: Where do we go from here?
Authors: Thomas Eiwegger, Katherine Anagnostou, Stefania Arasi, Philippe Bégin, Moshe Ben-Shoshan, Kirsten Beyer, Katharina Blumchen, Helen Brough, Jean-Christoph Caubet, Edmond S. Chan, Meng Chen, Sharon Chinthrajah, Carla M. Davis, Anne Des Roches, George Du Toit, Arnon Elizur, Stephen J. Galli, Geir Håland, Karin Hoffmann-Sommergruber, Harold Kim, Donald Y.M. Leung, Andrew Long, Antonella Muraro, Ulugbek B. Nurmatov, Giovanni B. Pajno, Vanitha Sampath, Jamie Saxena, Sayantani Sindher, Julia Upton, Margitta Worm, Kari C. Nadeau
Journal: Journal of Allergy and Clinical Immunology (2019)
光保护和维生素 D 状态
Authors: T. Passeron, R. Bouillon, V. Callender, T.L. Cestari, T. Diepgen, A.C. Green, J.C. van der Pols, B.A. Bernard, F. Ly, F. Bernerd, L. Marrot, M. Nielsen, M. Verschoore, N.G. Jablonski, A.R. Young
Journal: British Journal of Dermatology (2019)

维生素 D 是皮肤受阳光中紫外线(UVR)的照射后产生的。缺乏维生素 D (称为维生素 D 缺乏症)会导致骨骼变软变弱,从而导致骨骼畸形。尽管紫外线辐射是维生素 D 的主要来源,但它也是皮肤癌的主要原因,这引发了关于如何在理想(足够)的维生素 D 水平和防晒之间取得平衡的争论。 这篇综述旨在就防晒霜对维生素 D 状态的影响提供实用建议。由内分泌学、皮肤病学、光生物学、流行病学和生物人类学领域的 13 名专家组成的国际专家组在 2017 年 6 月的一天会议前回顾了有关维生素 D 水平和防晒霜使用的文献。他们检验了评估和确定维生素 D 充足性的最新方法、当前的公共卫生建议、日晒对维生素 D 的影响以及防晒霜使用的影响。 对理想的维生素 D 水平,尚无国际共识,建议之间也相差很大。在本次回顾中, ≥50 nmol/L 25(OH)D 的血液水平是最广泛认可的目标水平。结论是,每天使用广谱防晒霜(同时提供 UVA 和 UVB 防护效果)不会影响健康人的维生素 D 产生。但是,光敏性疾病患者是例外,因此,他们可以从维生素 D 筛查和补充中受益。
Increased Incidence of Viral Reactivation after T Cell Replete Haploidentical Stem Cell Transplantation in Association with Delayed Immune Reconstitution
Authors: Ioannis Tsonis, Dimitrios Karakasis, Maria Bouzani, Chara Giatra, Zois Mellios, Georgia Tounta, Tatiana Tzenou, Dimitra Oikonomopoulou, Eirini Grispou, Maria Katsareli, Maria-Eleni Karatza, Kimon Fountoulis, Themistoklis Karmiris, Stavros Gigantes, Ioannis Baltadakis
Journal: Blood (2019)
Protein-coding variants contribute to the risk of atopic dermatitis and skin-specific gene expression
Authors: Sören Mucha, Hansjörg Baurecht, Natalija Novak, Elke Rodríguez, Saptarshi Bej, Gabriele Mayr, Hila Emmert, Dora Stölzl, Sascha Gerdes, Eun Suk Jung, Frauke Degenhardt, Matthias Hübenthal, Eva Ellinghaus, Jan Christian Kässens, Lars Wienbrandt, Wolfgang Lieb, Martina Müller-Nurasyid, Melanie Hotze, Nick Dand, Sarah Grosche, Ingo Marenholz, Andreas Arnold, Georg Homuth, Carsten O. Schmidt, Ulrike Wehkamp, Markus M. Nöthen, Per Hoffmann, Lavinia Paternoster, Marie Standl, Klaus Bønnelykke, Tarunveer S. Ahluwalia, Hans Bisgaard, Annette Peters, Christian Gieger, Melanie Waldenberger, Holger Schulz, Konstantin Strauch, Thomas Werfel, Young-Ae Lee, Markus Wolfien, Philip Rosenstiel, Olaf Wolkenhauer, Stefan Schreiber, Andre Franke, Stephan Weidinger, David Ellinghaus
Journal: Journal of Allergy and Clinical Immunology (2019)
Abstract 11835: Evaluation of Cardiovascular Adverse Events Associated With Ibrutinib, Venetoclax and Idelalisib Used in Treatment of Chronic Lymphocytic Leukemia
Authors: Hetavi Mahida, Bharatsinh Gharia, Nene Ugoeke, Obiora Maludum, Arif Asif, Dawn Calderon
Journal: Circulation (2018)

Introduction: Chronic Lymphocytic leukemia(CLL) is a lymphoproliferative disorder most common leukemia in elderly populations. Ibrutinib, venetoclax and Idelalisib are approved for the treatment of...
Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden
Authors: Paola Minetto, Anna Candoni, Fabio Guolo, Marino Clavio, Maria Elena Zannier, Maurizio Miglino, Maria Vittoria Dubbini, Enrico Carminati, Anna Sicuranza, Sara Ciofini, Elisabetta Tedone, Nicoletta Colombo, Girolamo Pugliese, Riccardo Marcolin, Filippo Ballerini, Michele Cea, Marco Gobbi, Monica Bocchia, Renato Fanin, Roberto Massimo Lemoli
Journal: Blood (2019)
Impact of Modifying Conditioning and Immunosuppressive Strategies in Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Lymphoblastic Leukemia
Authors: Nawar Dakhallah, Mylène Beauchemin, Johanne Richer, Sonia Cellot, Pierre Teira, Michel Duval, Henrique Bittencourt
Journal: Blood (2019)
“Rehab for all!” Is it too early in pulmonary arterial hypertension?
Authors: Laurent Bertoletti, Hélène Bouvaist, Cécile Tromeur, Souad Bezzeghoud, Claire Dauphin, Irina Enache, Arnaud Bourdin, Marie-France Seronde, David Montani, Ségolène Turquier, Christophe Pison
Journal: European Respiratory Journal (2019)

Chronic pulmonary hypertension shares abnormalities found in chronic left heart failure and chronic respiratory failure, in which rehabilitation has been proposed [1, 2]. In a recent statement endorsed by the European Respiratory Society, Grünig et al. [3] proposed an exhaustive review of available data on rehabilitation in the setting of chronic pulmonary hypertension. The main messages proposed are "Specialised exercise training in patients with pulmonary hypertension appears to be effective, cost-efficient and safe." Rehabilitation appears to be beneficial in PAH patients, but more research is needed before increasing the level of evidence for recommendations. <http://bit.ly/33zutuZ> The authors thank Deirdre Epinat (Laniel Traduction SA, Saint-Etienne, 42000, France) for English editing.
In vivo antitumor activity of RAD001 (everolimus) in 58 specialized human tumor xenograft models.
Authors: T. O'Reilly, P.M.J. McSheehy, J. Brueggen, F. Hofmann, R. Cozens, T. Greiner, T. Metz, H. Fiebig, H.A. Lane, M. Ito
Journal: Cancer Research (2008)

2917  RAD001 (everolimus) is an orally-active mTOR inhibitor currently in Phase II/III clinical trials. RAD001 was evaluated for antitumor activity in 58 specialized models of cancer, which utilize human tumors that have only been passaged in immunosuppressed mice, therefore have not been subjected to selection pressures in vitro that tend to force human tumor cells to become undifferentiated and rapidly growing. The tested tumors included breast (5 lines), colorectal (9), gastric (3), lung (22 lines including adenocarcinomas, epidermoid cell, large cell and small cell histotypes), melanoma (6), ovarian (4), pancreatic (3) and renal (6). Overall, RAD001 (at 10 mg/kg, p.o., once per day, 5 days a week for 3 weeks) was an effective agent producing a mean T/C value of 27 ± 2 %, where T and C are the changes in mean relative tumor volume for the RAD001-treated mice and controls, respectively. Typically, the activity of RAD001 was to reduce the growth rate of the tumor. But minor, transient tumor regressions were observed and RAD001 also produced durable regressions in two tumors (one mammary and one lung adenocarcinoma). Mean T/C values of breast (9±5%), colorectal (41±7%), gastric (29±2%), lung adenocarcinomas (19±5%), epidermoid cell (38±3%), large cell (21±4%) and small cell (25±7%) lung, melanoma (32±8%), ovarian (28±4%), pancreatic (21±5%) and renal (29±9%) tumors were found for the specific histotypes. Treatment was well tolerated as shown by the mean body weight change of RAD001-treated mice indicating stable body weights (in the worst case), whereas in control mice increased body mass generally occurred. Use of an Efficacy Tolerability Quotient (ETQ) revealed a range of values suggestive of well-tolerated therapy, but of good to moderate antitumor effect. There was a weak correlation of in vitro IC50 values with tumor % T/C. Two-point (6 and 24h) pharmacokinetic analyses indicated that RAD001 penetration did not depend upon tumor histotype. Expression of the drug level in relation to the corresponding tumor cell line IC50 demonstrated a weak correlation with the antitumor effect, but sub-IC50 tumor levels were also associated with a wide range of antitumor effects from regressions to inactivity. When correcting for innate growth rate, the effect of RAD001 on growth rate reduction appeared to be a constant fraction of the control growth rate. These data indicate that RAD001 is a broadly active compound in experimental tumors derived from patient tumors.
Successful Treatment of Chimeric Antigen Receptor T Cell Therapy in Refractory or Relapsed Acute Leukemia Patients with TP53 alterations
Authors: Changju Qu, Jia Yin, Liqing Kang, Zheng Li, Haiping Dai, Xiaming Zhu, Lei Yu, Depei Wu, Xiaowen Tang
Journal: Blood (2019)
High-Throughput Immunofluorescence and Electron Tomography to Characterize Centrosomal Aberrations in Plasma Cell Neoplasia
Authors: Tobias Dittrich, Martin Schorb, Isabella Haberbosch, Elena Bausch, Mandy Börmel, Marco Cosenza, Hartmut Goldschmidt, Carsten Müller-Tidow, Marc S Raab, Ute Hegenbart, Stefan O. Schönland, Yannick Schwab, Alwin Krämer
Journal: Blood (2019)
DISEASES OF THE GASTROINTESTINAL TRACT
Authors: Franklin Hollander, Henry D. Janowitz
Journal: Annual Review of Medicine (1954)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), emerged in China in December 2019 and quickly spread around the globe, killing more than 4 million people and causing a severe economic crisis. ...Read More
ACC/AHA/HRS Versus ESC Guidelines for the Diagnosis and Management of Syncope
Authors: Zachary D. Goldberger, Bradley J. Petek, Michele Brignole, Win-Kuang Shen, Robert S. Sheldon, Monica Solbiati, Jean-Claude Deharo, Angel Moya, Mohamed H. Hamdan
Journal: Journal of the American College of Cardiology (2019)
Gene Expression Profiling of Structural and Functional High-Risk Multiple Myeloma
Authors: Moritz Binder, S. Vincent Rajkumar, Martha Q. Lacy, Jessica L. Haug, Angela Dispenzieri, Kimberly J. Henderson, Teresa K. Kimlinger, A. Keith Stewart, P. Leif Bergsagel, Shaji K. Kumar
Journal: Blood (2019)
Pilot Study on the Safety of Intravenous Arsenic Trioxide and Oral Realgar-Indigo Naturalis Formula Administrated in Children with Acute Promyelocytic Leukemia: A Single-Center Study
Authors: Linya Wang, Yuanyuan Zhang, Ruidong Zhang, Jiaole Yu, Ying Wu, Wei Lin, Peijing Qi, Jia Fan, Jing Li, Jiayan Lin, Xueling Zheng, Hairu Hu, Xiaoxia Peng, Hui Jiang, Huyong Zheng
Journal: Blood (2019)
Ebstein's Anomaly
Authors: S. GILBERT BLOUNT, MALCOLM C. MCCORD, IRA J. GELB
Journal: Circulation (1957)

Four cases of Ebstein's anomaly are described, revealing that the clinical features permit diagnosis in the majority of instances and that cardiac catheterization affords precise confirmation of the diagnosis. The occurrence of this anomaly in acyanotic adults is pointed out, and the similarity to acquired valvular rheumatic heart disease is stressed.
Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples
Authors: Maria Karvouni, Heyue Zhou, Arnika Kathleen Wagner, Qiangzhong Ma, Alamdar H. Baloch, Tong Zhu, Hong Zhang, Mari Gilljam, Andreas Lundqvist, Gunnar F. Kaufmann, Evren Alici
Journal: Blood (2019)